Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 6Gastrointestinal 4Thoracic 1NET 1Gynecologic 1

Conditions

Ovarian Neoplasms 208Carcinoma, Ovarian Epithelial 133Fallopian Tube Neoplasms 117Uterine Cervical Neoplasms 103Breast Neoplasms 76Endometrial Neoplasms 73Pancreatic Neoplasms 33Neoplasms 31Colonic Neoplasms 28Stomach Neoplasms 27Carcinoma, Non-Small-Cell Lung 27Prostatic Neoplasms 26Testicular Neoplasms 24Sarcoma 23Lung Neoplasms 23Melanoma 22Carcinoma, Renal Cell 22Rectal Neoplasms 21Colorectal Neoplasms 20Vaginal Neoplasms 18Uterine Cervical Dysplasia 18Carcinoma, Hepatocellular 18Neoplasm Metastasis 17Anus Neoplasms 17Precursor Cell Lymphoblastic Leukemia-Lymphoma 16Esophageal Neoplasms 16Brenner Tumor 16Urinary Bladder Neoplasms 15Leukemia, Lymphocytic, Chronic, B-Cell 15Vulvar Neoplasms 14

Interventions

sapanisertib 1aflibercept 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Adenoma, Islet Cell × Gynecologic × Clear all
NCT02159989 2025-10-20

Sapanisertib and Ziv-Aflibercept in Treating Patients With Recurrent Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

National Cancer Institute (NCI)

Phase 1 Completed
83 enrolled 21 charts
GastrointestinalGynecologic

Fibrolamellar hepatocellular carcinoma, Adenoma, Islet Cell, Neoplasm Metastasis, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡